Document is current
Any future updates will be listed below
-
Authors
Louis, Edouard https://orcid.org/0000-0002-1287-7075
Lee, Wan-Ju https://orcid.org/0000-0001-9263-6943
Litcher-Kelly, Leighann https://orcid.org/0000-0001-9005-6582
Ollis, Sarah https://orcid.org/0000-0002-1677-4081
Pranschke, Emma https://orcid.org/0000-0003-2044-850X
Fitzgerald, Kristina
Lacerda, Ana Paula https://orcid.org/0000-0002-0122-4183
Neimark, Ezequiel
Sanchez Gonzalez, Yuri https://orcid.org/0000-0001-7261-1933
Panés, Julian https://orcid.org/0000-0002-4971-6902
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03105128 at ClinicalTrials.govDocuments that mention this clinical trial
Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis
https://doi.org/10.1007/s41669-023-00419-w
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease
https://doi.org/10.1080/13543784.2019.1597053
Content Validity and Psychometric Evaluation of the Crohn’s Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn’s Disease
https://doi.org/10.1007/s12325-024-02923-9
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 12 March 2024
Accepted: 6 June 2024
First Online: 6 August 2024
Declarations
:
: Edouard Louis has received research grants from Janssen, Pfizer, and Takeda; received educational grants from AbbVie, Janssen, MSD, and Takeda; received speaker fees from AbbVie, Falk, Ferring, Hospira, Janssen, MSD, Pfizer, and Takeda; served on advisory boards for AbbVie, Arena, Celgene, Ferring, Galapagos, Gilead, Hospira, Janssen, MSD, Pfizer, and Takeda; and served as a consultant for AbbVie. Wan-Ju Lee, Yuri Sanchez Gonzalez, Ana Paula Lacerda, Kristina Fitzgerald, and Ezequiel Neimark are full-time employees of AbbVie and may hold AbbVie stock and/or stock options. At the time of this manuscript’s development, Leighann Litcher-Kelly, Sarah Ollis, and Emma Pranschke were employed by Adelphi Values LLC, which received payment from AbbVie Inc. to support the research activities presented in this publication. Emma Pranschke is currently employed by Analysis Group. Julian Panés received financial support for research from AbbVie and Pfizer; consultancy fees/honorarium from AbbVie, Arena, Athos, Atomwise, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech/Roche, GlaxoSmithKline, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer, Progenity, Protagonist, Revolo, Robarts, Takeda, Theravance and Wasserman; reports payment for lectures including service on speaker bureau from Abbott, Ferring, Janssen, Pfizer and Takeda; and reports payment for development of educational presentations from Abbott, Janssen, Pfizer Roche and Takeda.
: The study protocols and all study documents were approved by ethical review committees. All participants in this research provided informed consent for their participation (or assent and caregiver consent for individuals under the age of 18).
